There is one clinical trial.
one-centered, open, prospective, non-randomized, controlled clinical study will be aimed at creating remote monitoring system for patients' condition and the development of methodological approaches and its usage for conducting patients, who had myocardial infraction and who has a very high risk of developing an unfavorable outcome.
At the end of a 12 month observation with the registration of unfavorable cardiovascular occasions (death from cardiovascular reasons, nonfatal myocardial infraction, cerebral stroke, necessity for repeated revascularization of the coronary arteries) based on the analysis of non-genetic and genetic factors (polymorphism of genes Thr174Met and Met235Thr in gene angiotensinogen, Arg389Gly and Ser49Gly in gene adrenoceptor beta 1, Ser447Ter in gene lipoprotein lipase and Leu28Pro in gene apolipoprotein E, Trp212Ter and G681A in gene cytochrome P450 family 2 subfamily C member 19) factors of unfavorable prognosis will be identified and considering which group of patients requires the use of remote monitoring system will be formed. --- Thr174Met --- --- Met235Thr --- --- Arg389Gly --- --- Ser49Gly --- --- Leu28Pro ---
Description: the number of deaths from cardiovascular causesMeasure: cardiovascular mortality Time: 12 months
Description: incidence of acute myocardial infarctionMeasure: acute myocardial infarction Time: 12 months
Description: incidence of cerebral strokeMeasure: cerebral stroke Time: 12 months
Description: frequency of repeated revascularization of coronary arteriesMeasure: revascularization Time: 12 months
Description: frequency of hospitalization about the progression of coronary heart diseaseMeasure: hospitalization Time: 12 months